- Home
- ALX vs PHAR Comparison
ALX vs PHAR Comparison
Compare ALX & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALX | PHAR |
|---|---|---|
| Founded | 1928 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ALX | PHAR |
|---|---|---|
| Price | $218.44 | $17.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 44.8K | 21.0K |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | ★ 8.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.14 | 0.00 |
| Revenue | $215,838,000.00 | ★ $362,274,000.00 |
| Revenue This Year | N/A | $24.80 |
| Revenue Next Year | N/A | $6.84 |
| P/E Ratio | ★ $30.57 | $3,084.39 |
| Revenue Growth | N/A | ★ 26.78 |
| 52 Week Low | $184.76 | $7.50 |
| 52 Week High | $260.84 | $18.12 |
Technical Indicators
Market Signals| Indicator | ALX | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 51.08 | 60.83 |
| Support Level | $212.03 | $15.76 |
| Resistance Level | $218.02 | $17.35 |
| Average True Range (ATR) | 4.48 | 0.77 |
| MACD | 1.21 | 0.02 |
| Stochastic Oscillator | 85.32 | 89.41 |
Price Performance
Historical ComparisonAbout ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.